Global Veterinary Monoclonal Antibodies Market Projected to Reach $1.8 Billion by 2030 at 14.8% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Antibacterial Silver Spray Market By 2030 Starting From Its 2026 Size?
The market size for monoclonal antibodies in veterinary health has experienced significant expansion recently. It is projected to increase from $0.92 billion in 2025 to $1.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The historical growth in this sector can be attributed to the rising prevalence of canine cancers, an increasing incidence of autoimmune disorders in pets, the limited availability of targeted therapies, the expansion of veterinary hospitals, and a greater awareness of advanced veterinary treatments.
The monoclonal antibodies in veterinary health market is anticipated to experience significant expansion in the foreseeable future. This market is projected to reach $1.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.8%. This projected increase can be attributed to several factors such as technological advancements in mAb engineering, the growing adoption of species-specific therapies, escalating investment in veterinary oncology and dermatology, the proliferation of personalized veterinary medicine, and the expanding global veterinary healthcare infrastructure. Prominent trends expected during this forecast period include the rise of monoclonal antibody-based treatments for canine cancer, increased utilization of mAbs for autoimmune disorders in dogs, the broadening of veterinary dermatology applications, a greater uptake of targeted pain management therapies, and the ongoing development of species-specific antibody therapies for cats, horses, and livestock.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp
What Primary Drivers Are Shaping The Development Of The Antibacterial Silver Spray Market?
Future expansion of the monoclonal antibodies in veterinary health market is anticipated due to an increase in animal disease occurrences. This surge in animal disease frequency stems from intensified agricultural methods, which elevate the potential for infectious disease transmission, and global warming, which broadens the habitat of disease carriers like ticks and mosquitoes. Monoclonal antibodies prove highly effective in managing animal illnesses because they precisely target particular pathogens or proteins engaged in disease mechanisms, thus providing accurate and impactful therapies. An illustrative example comes from a June 2024 report by GOV.UK, a UK-based government website, which revealed that between April 2023 and March 2024, the count of animals culled due to TB incidents climbed by 5% in England, reaching 21,298, and by 17% in Wales, totaling 11,197. Consequently, the increasing occurrences of animal diseases are propelling the expansion of the monoclonal antibodies in veterinary health market.
Which Segment Categories Define The Antibacterial Silver Spray Market?
The monoclonal antibodies in veterinary health market covered in this report is segmented –
1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products
2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals
3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications
4) By Route Of Administration: Injectable, Oral, Topical
5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs
2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone
3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine
4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil
5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics
What Major Market Trends Are Driving Changes In The Monoclonal Antibodies In Veterinary Health Market?
Leading companies in the monoclonal antibodies in veterinary health market are concentrating on creating innovative therapeutic solutions for animals, including anti-NGF monoclonal antibody treatments, to manage issues like chronic pain and inflammation. An anti-NGF monoclonal antibody treatment is a therapeutic strategy that targets and inhibits nerve growth factor (NGF) to lessen pain and inflammation in animals experiencing chronic pain conditions. For example, in May 2023, Zoetis, a US-based animal health company, obtained FDA approvals for Librela (bedinvetmab injection), which is the first monoclonal antibody treatment for managing pain linked to osteoarthritis (OA) in dogs, given as a once-monthly injection, and also for Apoquel Chewable, the initial chewable medication specifically for addressing allergic itch and inflammation in dogs aged one year or older. Librela functions as a monoclonal antibody that precisely targets and inhibits nerve growth factor (NGF). By obstructing NGF, Librela assists in preventing pain signals from reaching the brain, thereby decreasing the perception of pain in dogs with osteoarthritis. Librela signifies a major breakthrough in veterinary pain management, offering a new method for treating chronic pain in dogs.
Who Are The Top Companies Competing In The Antibacterial Silver Spray Market?
Major companies operating in the monoclonal antibodies in veterinary health market are Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, ImmuCell
Read the full monoclonal antibodies in veterinary health market report here:
How Does The Antibacterial Silver Spray Market Perform Across Major Global Regions?
North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Antibacterial Silver Spray Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20575&type=smp
Browse Through More Reports Similar to the Global Monoclonal Antibodies In Veterinary Health Market 2026, By The Business Research Company
Veterinary Reference Laboratory Global Market Report 2026
Veterinary Stereotactic Radiosurgery System Global Market Report 2026
Veterinary Active Pharmaceutical Ingredients Manufacturing Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
